Adlai Nortye’s (ANL) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Adlai Nortye (NASDAQ:ANL) in a research report released on Friday morning,Weiss Ratings reports.

Adlai Nortye Stock Performance

Shares of Adlai Nortye stock opened at $1.65 on Friday. The business has a fifty day simple moving average of $1.72 and a 200-day simple moving average of $1.71. Adlai Nortye has a fifty-two week low of $1.10 and a fifty-two week high of $3.89.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.